Marked Hyperbilirubinemia Associated with Primary Myelofibrosis Responsive to Ruxolitinib

Sunny Sandhu; Hunza Chaudhry; Sharon Zhang; Devang Prajapati

doi:10.1155/2022/9630996

Marked Hyperbilirubinemia Associated with Primary Myelofibrosis Responsive to Ruxolitinib

Case Reports Hepatol. 2022 May 28:2022:9630996. doi: 10.1155/2022/9630996. eCollection 2022.

Authors

Sunny Sandhu¹, Hunza Chaudhry¹, Sharon Zhang², Devang Prajapati³

Affiliations

¹ Department of Internal Medicine, University of California, San Francisco- Fresno, Fresno, CA, USA.
² Department of Pathology, Community Medical Centers, Fresno, CA, USA.
³ Department of Gastroenterology & Hepatology, University of California, San Francisco- Fresno, Fresno, CA, USA.

Abstract

Primary myelofibrosis (PMF) is a chronic myeloproliferative disorder seen in older adults which can present both with hepatosplenomegaly as well as mild nonspecific liver enzyme abnormalities. Mild elevations in bilirubin can occasionally be seen due to both intravascular hemolysis as well as extramedullary hematopoiesis. Marked hyperbilirubinemia as a presenting sign of PMF progression, however, has not been reported. We present the case of a patient with a remote diagnosis of PMF, who presented with marked hyperbilirubinemia with a notable response to ruxolitinib.

Publication types

Case Reports